Deciphera to Acquire UroGen Pharma for $750M

TL;DR

Deciphera is buying UroGen for $750M cash, deal expected Q3 2025.

AI Summary

UroGen Pharma Ltd. announced on June 12, 2025, that it has entered into a definitive agreement to be acquired by Deciphera Pharmaceuticals, LLC. The transaction is valued at approximately $750 million, with Deciphera acquiring all outstanding shares of UroGen for $17.10 per share in cash. This acquisition is expected to close in the third quarter of 2025, subject to customary closing conditions.

Why It Matters

This acquisition significantly consolidates the uro-oncology space, potentially impacting future treatment options and market competition for bladder cancer therapies.

Risk Assessment

Risk Level: medium — The deal is subject to customary closing conditions and regulatory approvals, which could delay or prevent its completion.

Key Numbers

• $750M — Acquisition Value (Total cash consideration for UroGen Pharma)
• $17.10 — Per Share Price (Cash amount each UroGen shareholder will receive)

Key Players & Entities

• UroGen Pharma Ltd. (company) — Registrant
• Deciphera Pharmaceuticals, LLC (company) — Acquiring entity
• $750 million (dollar_amount) — Acquisition valuation
• $17.10 (dollar_amount) — Per share acquisition price
• June 12, 2025 (date) — Date of agreement
• Third quarter of 2025 (date) — Expected closing period

FAQ

From the Filing

0001193125-25-140339.txt : 20250613 0001193125-25-140339.hdr.sgml : 20250613 20250613080029 ACCESSION NUMBER: 0001193125-25-140339 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20250612 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250613 DATE AS OF CHANGE: 20250613 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UroGen Pharma Ltd. CENTRAL INDEX KEY: 0001668243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38079 FILM NUMBER: 251044772 BUSINESS ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 BUSINESS PHONE: 972 9 770 7601 MAIL ADDRESS: STREET 1: 9 HA'TA'ASIYA ST CITY: RA'ANANA STATE: L3 ZIP: 4365007 8-K 1 d98388d8k.htm 8-K 8-K false 0001668243 0001668243 2025-06-12 2025-06-12     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2025     UROGEN PHARMA LTD. (Exact name of registrant as specified in its charter)       Israel   001-38079   98-1460746 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   400 Alexander Park Drive , 4th Floor Princeton , New Jersey   08540 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: +1 (646) 768-9780     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Ordinary Shares, par value NIS 0.01 per share   URGN   The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On June 12, 2025, the U.S. Food and Drug Administration (“FDA”) approved ZUSDURI ™ (mitomycin), formerly known as UGN-102, a sustained-release gel formulation of mitomycin for the treatment of adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer (“LG-IR-NMIBC”). The approval of ZUSDURI is based on data from the pivotal Phase 3 ENVISION trial in which 78% of patients achieved complete response at three months, and 79% of those responders maintained complete response at 12 months after the three-month visit. The most common (≥ 10%) adverse reactions, including laboratory abnormalities, that occurred in patients were increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increase